Pulse Biosciences
PLSE
45.55
+1.14
+2.57%
Pulse Biosciences
US · PLSE
#2388 by market cap
Listed 2016
45.55
+1.14
+2.57%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 21 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.3 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 16.54% +0.32pp
- Institutions
- 157 +21
- As of
- 2026/Q3 vs. prior period
Holder types
Individual/Insider68.04%
Mutual Fund9.55%
Hedge Fund3.48%
Public Company2.23%
Private Company0.96%
Sovereign Wealth Fund0.14%
Other15.43%
Top holders as of 2026-05-11
Robert Duggan
66.38% · 48.82M sh
BlackRock
2.28% · 1.67M sh
Bank of America Corporation
1.97% · 1.45M sh
Vanguard Capital Management, LLC
1.28% · 937.95K sh
Mahkam Zanganeh
1.19% · 873.47K sh
Portolan Capital Management, LLC
1.02% · 753.33K sh
T. Rowe Price Group, Inc.
1.02% · 748.64K sh
Balyasny Asset Management L.P.
0.98% · 718.10K sh
Genius Inc.
0.86% · 630.11K sh
Citadel Advisors LLC
0.85% · 626.51K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| Robert Duggan | Independent Co-Chairman | 66.38% |
| Mahkam Zanganeh | Independent Director | 1.19% |
| Darrin Uecker | CTO & Director | 0.39% |
| Kevin Danahy | Former Chief Commercial Officer | 0.06% |
| Paul LaViolette | President, CEO & Co-Chairman of the Board | 0.02% |
| Liane Teplitsky | Chief Operating Officer | 0.01% |
| Richard van den Broek | Independent Director | -- |
| Burke Barrett | Former Chief Executive Officer | -- |
| Maria Degois-Sainz | Independent Director | -- |
| Manmeet Soni | Lead Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Liane Teplitsky | Chief Operating Officer | Open Market Acquisition | +2,025 | $48.80–49.95 |
| 2026-08-27 | Liane Teplitsky | Chief Operating Officer | Open Market Acquisition | +2,070 | $48.24–48.35 |
| 2026-08-07 | Liane Teplitsky | Chief Operating Officer | Other Derivative Acquisition | +200,000 | -- |
| 2026-08-07 | Liane Teplitsky | Chief Operating Officer | Other Derivative Acquisition | +700,000 | $19.06 |
| 2026-06-10 | Richard van den Broek | Independent Director | Other Derivative Acquisition | +38,423 | $26.89 |
| 2026-06-10 | Robert Duggan | Independent Co-Chairman | Other Derivative Acquisition | +42,495 | $26.89 |
| 2026-06-10 | Maria Degois-Sainz | Independent Director | Other Derivative Acquisition | +33,793 | $26.89 |
| 2026-06-10 | Mahkam Zanganeh | Independent Director | Other Derivative Acquisition | +44,504 | $26.89 |
| 2026-06-10 | Manmeet Soni | Lead Independent Director | Other Derivative Acquisition | +30,000 | $26.89 |
| 2026-05-10 | Paul LaViolette | President, CEO & Co-Chairman of the Board | Open Market Acquisition | +15,000 | $19.69 |
| 2026-05-10 | Robert Duggan | Independent Co-Chairman | Open Market Acquisition | +660,233 | $19.69 |
| 2026-03-22 | Darrin Uecker | CTO & Director | Other Derivative Acquisition | +100,000 | -- |
| 2026-02-17 | Kevin Danahy | Former Chief Commercial Officer | Derivative Exercise and Sale | -5,000 | $1.53–23.64 |
| 2026-02-16 | Kevin Danahy | Former Chief Commercial Officer | Derivative Exercise and Sale | -60,000 | $1.53–23.63 |
| 2026-02-11 | Kevin Danahy | Former Chief Commercial Officer | Intent to Sell (Form 144) | -50,000 | $25.25 |
| 2026-02-10 | Kevin Danahy | Former Chief Commercial Officer | Derivative Exercise and Sale | -60,000 | $1.53–25.20 |
| 2026-02-08 | Kevin Danahy | Former Chief Commercial Officer | Intent to Sell (Form 144) | -75,000 | $20.75 |
| 2026-02-04 | Maria Degois-Sainz | Independent Director | Other Derivative Acquisition | +53,104 | $13.69–14.72 |
| 2025-10-01 | Kevin Danahy | Former Chief Commercial Officer | Derivative Exercise and Sale | -4,600 | $1.53–18.53 |
| 2025-09-18 | Kevin Danahy | Former Chief Commercial Officer | Derivative Exercise and Sale | -20,400 | $1.53–18.49 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Pulse Biosciences discussion 0 comments